Abstract
A 1987 survey of 365 members of the Retina and Vitreous societies revealed that use of long-acting intraocular gases was both widespread and frequent. However, despite the expanded use of intravitreal gases and the stated intention of the Food and Drug Administration to approve premarket applications for use of sulfur hexafluoride and perfluoropropane, there are still limitations in the ready availability of these substances. Therefore, we conducted another survey to determine current patterns of intraocular gas use. The results indicate that more surgeons are using long-acting gases. The data also demonstrate the selective use of pneumatic retinopexy with geographic pockets of increased retinopexy use in California and Florida. Finally, 100% of respondents now indicate that they consider the use of sulfur hexafluoride and perfluoropropane to be a standard of care.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
